StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
TRXBTRex Bio, Inc.
stockpulse.co.kr
Nasdaq
$13.84▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

8
  • 10.16After-hours26.10.17 07:02
    SCHEDULE 13GOwnership#●●●

    TRex Bio, Inc.

    Pfizer Inc. and Pfizer Ventures (US) LLC have entered into a joint filing agreement for Schedule 13G regarding their stake in TRex Bio, Inc. This filing confirms the legal arrangement for the entities to report their share ownership collectively.…more

    $13.84+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.16After-hours26.10.17 05:19
    SCHEDULE 13DOwnership

    TRex Bio, Inc.

    Eli Lilly & Co has filed a Schedule 13D regarding its acquisition of shares in TRex Bio, Inc. This filing formalizes Eli Lilly's position as a significant shareholder in TRex Bio, indicating a strategic development between the two companies.…more

    $13.84+0.00%vs prev close
    View filingShare
  • 10.16Regular26.10.17 04:53
    SCHEDULE 13DOwnership

    TRex Bio, Inc.

    SV Biotech Crossover Opportunities Fund LP has filed a Schedule 13D regarding its ownership of TRex Bio, Inc. common stock. The filing outlines the joint filing agreement and details regarding the investment committee members of its general partner, SV BCO I GP LLP.…more

    $13.84+0.00%vs prev close
    View filingShare

7 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.16After-hours26.10.17 05:23
    #●●●#●●●

    Eli Lilly Acquires 19.9% Stake in TRex Bio via IPO Investment

    Eli Lilly has invested approximately $12.3 million to acquire a 19.9% stake in TRex Bio through its recent IPO. The investment consists of converted preferred shares and newly purchased common stock at the offering price.…more

    $13.84+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 10.13After-hours26.10.14 05:47

    ●●●●●●●● ●●●●● ●●●●●●

    Clinical-stage biotech company TRexBio has successfully closed its initial public offering of 8.33 million shares at $14.00 per share. The company raised approximately $116.7 million in gross proceeds to support its drug discovery and development efforts.…more

    $13.84+0.00%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →